# PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

> **NCT04789434** · PHASE3 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Transplantation
- Chemotherapy

## Interventions

- **DRUG:** PD-1 Inhibitor Tislelizumab maintenance therapy

## Key facts

- **NCT ID:** NCT04789434
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2023-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789434, "PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04789434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*